Drug | KEGG | ATC | Product | Target | Biomarker | KEGG VARIANT |
KEGG NETWORK |
Maralixibat | D10952 | A05AX04 | Livmarli | SLC10A2 | ABCB11 mutation | 8647v1 | |
Mecasermin | D03297 | H01AC03 | Increlex | IGF1R GHR |
GH1 deletion (developed neutralizing antibodies to GH) | ||
Tegafur, gimeracil and oteracil potassium | D06399 | L01BC53 | Ts-1 | ESR1 positive HER2 negative |
2099v1 | ||
Imatinib | D01441 | L01EA01 | Gleevec | BCR-ABL FIP1L1-PDGFRA KIT PDGFR |
Philadelphia chromosome (BCR-ABL fusion gene) FIP1L1-PDGFRA fusion gene KIT mutation D816V negative PDGFR rearrangement |
25v1 |
nt06276 |
Dasatinib | D06414 | L01EA02 | Sprycel | BCR-ABL | Philadelphia chromosome, BCR-ABL T315I mutation | ||
Nilotinib | D06413 | L01EA03 | Tasigna | BCR-ABL | Philadelphia chromosome (BCR-ABL fusion gene) UGT1A1*28 allele homozygotes |
54658v1 | nt06276 |
Bosutinib | D09728 | L01EA04 | Bosulif | BCR-ABL | Philadelphia chromosome (BCR-ABL fusion gene) | ||
Ponatinib | D09951 | L01EA05 | Iclusig | BCR-ABL | Philadelphia chromosome, (BCR-ABL fusion gene) T315I mutation | ||
Asciminib | D11404 | L01EA06 | Scemblix | BCR-ABL | Philadelphia chromosome, (BCR-ABL fusion gene) T315I mutation | 25v1 | nt06276 |
Gefitinib | D01977 | L01EB01 | Iressa | EGFR | EGFR exon 19 deletion or exon 21 L858R mutation | 1956v2 | nt06266 |
Erlotinib | D04023 | L01EB02 | Tarceva | EGFR | EGFR exon 19 deletion or exon 21 L858R mutation | 1956v2 | nt06266 |
Afatinib | D09733 | L01EB03 | Giotrif | EGFR | EGFR exon 19 deletion or exon 21 L858R mutation | 1956v2 | nt06266 |
Osimertinib | D10766 | L01EB04 | Tagrisso | EGFR | EGFR T790M mutation | 1956v3 | nt06266 |
Dacomitinib | D10514 | L01EB07 | Vizimpro | EGFR | EGFR exon 19 deletion or exon 21 L858R mutation | 1956v2 | nt06266 |
Lazertinib | D12245 | L01EB09 | Lazcluze | EGFR | EGFR exon 19 deletion or exon 21 L858R mutation | 1956v2 | nt06266 |
Mobocertinib | D11969 | L01EB10 | Exkivity | EGFR | EGFR exon 20 insertion mutation | 1956v2 | nt06266 |
Vemurafenib | D09996 | L01EC01 | Zelboraf | BRAF | BRAF V600E mutation NRAS mutation |
673v1 | nt06268 |
Dabrafenib | D10104 | L01EC02 | Tafinlar | BRAF | BRAF V600E mutation G6PD deficiency |
673v1 | nt06268 |
Encorafenib | D11053 | L01EC03 | Braftovi | BRAF | BRAF V600E/K mutation | 673v1 | nt06268 |
Crizotinib | D09731 | L01ED01 | Xalkori | EML4-ALK ROS1 |
EML4-ALK fusion gene ROS1 fusion gene |
238v1 6098v1 |
nt06266 |
Ceritinib | D10551 | L01ED02 | Zykadia | EML4-ALK | ALK gene rearrangement | 238v2 | nt06266 |
Alectinib | D10450 | L01ED03 | Alecensa | EML4-ALK | ALK gene rearrangement | 238v2 | nt06266 |
Brigatinib | D10866 | L01ED04 | Alunbrig | EML4-ALK | ALK gene rearrangement | 238v2 | nt06266 |
Lorlatinib | D11012 | L01ED05 | Lorbrena | EML4-ALK | ALK gene rearrangement | 238v2 | nt06266 |
Trametinib | D10176 | L01EE01 | Mekinist | MEK | BRAF V600E/K mutation | 673v1 | nt06268 |
Cobimetinib | D10615 | L01EE02 | Cotellic | MEK | BRAF V600E/K mutation | 673v1 | nt06268 |
Binimetinib | D10604 | L01EE03 | Mektovi | MEK | BRAF V600E/K mutation | 673v1 | nt06268 |
Palbociclib | D10372 | L01EF01 | Ibrance | CDK4/6 | ESR1 positive HER2 negative |
2099v1 | |
Ribociclib | D10979 | L01EF02 | Kisqali | CDK4/6 | ESR1 positive HER2 negative |
2099v1 | |
Abemaciclib | D10688 | L01EF03 | Verzenio | CDK4/6 | ESR1 positive HER2 negative MKI67 score |
||
Everolimus | D02714 | L01EG02 L04AH02 |
Afinitor Zortress |
MTOR | ESR1 positive HER2 negative |
2099v1 | |
Lapatinib | D04024 | L01EH01 | Tykerb | EGFR HER2 |
HER2 positive ESR1, PGR positive HLA-DQA1*0201 or HLA-DRB1*0701 allele carrier |
2064v1 | nt06270 |
Neratinib | D10898 | L01EH02 | Nerlynx | EGFR HER2 HER4 |
HER2 positive | 2064v1 2064v3 |
nt06270 |
Tucatinib | D11141 | L01EH03 | Tukysa | HER2 HER3 |
HER2 positive RAS wild type |
2064v1 2064v3 |
nt06270 |
Momelotinib | D10889 | L01EJ04 | Ojjaara | JAK1 JAK2 ACVR1 |
JAK2 mutation | 3717v1 | |
Fruquintinib | D11977 | L01EK04 | Fruzaqla | VEGFR1 VEGFR2 VEGFR3 |
RAS wild type | ||
Ibrutinib | D10223 | L01EL01 | Imbruvica | BTK | Chromosome 17p deletion Chromosome 11q deletion |
||
Alpelisib | D11011 | L01EM03 | Piqray | PIK3CA | PIK3CA mutation ESR1 positive HER2 negative |
5290v1 2099v1 |
nt06270 |
Erdafitinib | D10927 | L01EN01 | Balversa | FGFR3 FGFR2 |
FGFR3,2 genetic alterations | 2261v2 2263v2 |
nt06265 |
Pemigatinib | D11417 | L01EN02 | Pemazyre | FGFR2 | FGFR2 fusion gene | 2263v2 | |
Infigratinib | D11611 | L01EN03 | Truseltiq | FGFR2 FGFR1 FGFR3 |
FGFR2 mutation | 2263v2 2263v1 |
|
Futibatinib | D11725 | L01EN04 | Lytgobi | FGFR2 | FGFR2 fusion gene | 2263v2 | |
Midostaurin | D05029 | L01EX10 | Rydapt | FLT3 (CD135) | FLT3 mutation | 2322v1 2322v2 |
|
Quizartinib | D09956 | L01EX11 | Vanflyta | FLT3 (CD135) | FLT3 mutation | 2322v2 | |
Larotrectinib | D11138 | L01EX12 | Vitrakvi | TRKA | TRK positive | ||
Gilteritinib | D10800 | L01EX13 | Xospata | FLT3 (CD135) | FLT3 mutation | 2322v1 2322v2 |
|
Entrectinib | D10926 | L01EX14 | Rozlytrek | NTRK1 ROS1 |
NTRK1 fusion gene ROS1 fusion gene |
4914v1 6098v1 |
|
Capmatinib | D10891 | L01EX17 | Tabrecta | MET | MET exon 14 skipping | 4233v4 | nt06266 |
Avapritinib | D11279 | L01EX18 | Ayvakit | KIT PDGFRA |
KIT mutation PDGFRA mutation |
3815v1 5156v2 |
|
Tepotinib | D11073 | L01EX21 | Tepmetko | MET | MET exon 14 skipping | 4233v4 | nt06266 |
Selpercatinib | D11713 | L01EX22 | Retevmo | RET | RET fusion positive | 5979v1 5979v2 |
nt06274 nt06266 |
Pralsetinib | D11712 | L01EX23 | Gavreto | RET | RET fusion positive | 5979v1 | nt06266 |
Capivasertib | D11371 | L01EX27 | Truqap | AKT | HER2 negative ESR1 positive PIK3CA/AKT1/PTEN mutations |
207v1 2099v1 |
nt06530 |
Repotrectinib | D11454 | L01EX28 | Augtyro | ROS1 NTRK1 NTRK2 NTRK3 |
ROS1 fusion gene | 6098v1 | |
Rituximab | D02994 | L01FA01 | Rituxan | CD20 | CD20 positive | ||
Ofatumumab | D09314 | L01FA02 | Arzerra | CD20 | CD20 positive | ||
Obinutuzumab | D09321 | L01FA03 | Gazyva | CD20 | CD20 positive | ||
Inotuzumab ozogamicin | D08933 | L01FB01 | Besponsa | CD22 | CD22 positive | ||
Trastuzumab | D03257 | L01FD01 | Herceptin | HER2 | HER2 overexpression | 2064v1 | nt06270 nt06261 |
Pertuzumab | D05446 | L01FD02 | Perjeta | HER2 | HER2 positive | 2064v1 2064v3 |
nt06270 |
Trastuzumab emtansine | D09980 | L01FD03 | Kadcyla | HER2 | HER2 positive | 2064v1 2064v3 |
nt06270 |
Trastuzumab deruxtecan | D11529 | L01FD04 | Enhertu | HER2 | HER2 positive | 2064v1 2064v3 |
nt06270 |
Margetuximab | D10446 | L01FD06 | Margenza | HER2 | HER2 positive | 2064v1 2064v3 |
|
Cetuximab | D03455 | L01FE01 | Erbitux | EGFR | EGFR expression KRAS wild type BRAF V600E mutation |
673v1 | |
Panitumumab | D05350 | L01FE02 | Vectibix | EGFR | EGFR expression, KRAS wild type | nt06270 | |
Nivolumab | D10316 | L01FF01 | Opdivo | PD1 | PDL1 positive BRAF V600 mutation Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) |
||
Pembrolizumab | D10574 | L01FF02 | Keytruda | PD1 | PDL1 positive Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) HER2 negative ESR1, PGR negative |
||
Durvalumab | D10808 | L01FF03 | Imfinzi | PDL1 | PDL1 positive Mismatch repair deficiency (dMMR) |
||
Avelumab | D10817 | L01FF04 | Bavencio | PDL1 | PDL1 positive | ||
Atezolizumab | D10773 | L01FF05 | Tecentriq | PDL1 | PDL1 positive HER2 negative ESR1, PGR negative BRAF V600E/K mutation |
673v1 | |
Cemiplimab | D11108 | L01FF06 | Libtayo | PD1 | PDL1 positive | ||
Dostarlimab | D11366 | L01FF07 | Jemperli | PDCD1 | Mismatch repair deficiency (dMMR) | ||
Ramucirumab | D09371 | L01FG02 | Cyramza | VEGFR2 | EGFR exon 19 deletion or exon 21 L858R mutation | 1956v2 | |
Gemtuzumab ozogamicin | D03259 | L01FX02 | Mylotarg | CD33 | CD33 positive | ||
Ipilimumab | D04603 | L01FX04 | Yervoy | CTLA4 | Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) | ||
Brentuximab vedotin | D09587 | L01FX05 | Adcetris | CD30 | CD30 positive | ||
Dinutuximab | D10559 | L01FX06 | Unituxin | GD2 | MYCN amplification | ||
Blinatumomab | D09325 | L01FX07 | Blincyto | CD19 | Philadelphia chromosome (BCR-ABL fusion gene) negative | ||
Mogamulizumab | D09761 | L01FX09 | Poteligeo | CCR4 | CCR4 positive | ||
Tafasitamab | D11601 | L01FX12 | Monjuvi | CD19 | CD19 positive | ||
Sacituzumab govitecan | D10985 | L01FX17 | Trodelvy | TOP1 TACSTD2 |
HER2 negative ESR1 positive |
2099v1 | |
Amivantamab | D11894 | L01FX18 | Rybrevant | EGFR MET |
EGFR exon 20 insertion mutation | 1956v2 | |
Olaparib | D09730 | L01XK01 | Lynparza | PARP1 | BRCA1,2 mutation HER2 negative |
672v1 675v1 |
|
Niraparib | D11895 | L01XK02 | Zejula | PARP1 | BRCA1,2 mutation or wild type | 672v1 675v1 |
|
Rucaparib | D10982 | L01XK03 | Rubraca | PARP1 | BRCA1,2 mutation | 672v1 675v1 |
|
Talazoparib | D10733 | L01XK04 | Talzenna | PARP1/2 | BRCA1,2 mutation HER2 negative Homologous recombination repair gene (HRR) mutations |
672v1 675v1 |
|
Tisagenlecleucel-T | D11386 | L01XL04 | Kymriah | CD19 | CD19 positive | ||
Omacetaxine | D08956 | L01XX40 | Synribo | CCND1 | Philadelphia chromosome (BCR-ABL fusion gene) negative | ||
Venetoclax | D10679 | L01XX52 | Venclexta | BCL2 | Chromosome 17p deletion | ||
Enasidenib | D11044 | L01XM01 | Idhifa | IDH2 | IDH2 mutation | 3418v1 | |
Ivosidenib | D11090 | L01XM02 | Tibsovo | IDH1 | IDH1 mutation | 3417v1 | |
Olutasidenib | D12483 | (L01XM03) | Rezlidhia | IDH1 | IDH1 mutation | 3417v1 | |
Tazemetostat | D11485 | L01XX72 | Tazverik | EZH2 | EZH2 mutation positive | 2146v1 | |
Sotorasib | D12055 | L01XX73 | Lumakras | KRAS | KRAS mutation | 3845v1 | nt06266 |
Tebentafusp | D12296 | L01XX75 | Kimmtrak | CD3D CD3E CD3G |
HLA-A*0201 positive | ||
Adagrasib | D12301 | L01XX77 | Krazati | KRAS | KRAS mutation | 3845v1 | |
Mirvetuximab soravtansine | D10954 | L01FX26 | Elahere | FOLR1 TUBB |
FOLR1 positive | ||
Tamoxifen | D00966 | L02BA01 | Nolvadex | NR3A (ESR) | ESR1, PGR positive Factor V Leiden negative Prothrombin G20210A negative |
2099v1 2153v1 2147v1 |
|
Fulvestrant | D01161 | L02BA03 | Faslodex | NR3A (ESR) | ESR1, PGR positive HER2 negative |
||
Elacestrant | D11672 | L02BA04 | Orserdu | NR3A1 (ESR1) | ER positive ESR1 mutation HER2 negative |
2099v1 2099v2 |
|
Anastrozole | D00960 | L02BG03 | Arimidex | CYP19A1 (ARO) | ESR1, PGR positive | 2099v1 | |
Letrozole | D00964 | L02BG04 | Femara | CYP19A1 (ARO) | ESR1, PGR positive | 2099v1 | |
Exemestane | D00963 | L02BG06 | Aromasin | CYP19A1 (ARO) | ESR1, PGR positive | 2099v1 | |
Satralizumab | D11079 | L04AC19 | Enspryng | IL6R | anti-AQP4 antibody positive | ||
Inebilizumab | D11757 | L04AG10 | Uplizna | CD19 | anti-AQP4 antibody positive | ||
Rozanolixizumab | D12182 | L04AG16 | Rystiggo | FCGRT | anti-ACHR antibody positive anti-MUSK antibody positive |
||
Eculizumab | D03940 | L04AJ01 | Soliris | C5 | anti-ACHR antibody positive anti-AQP4 antibody positive |
||
Ravulizumab | D11054 | L04AJ02 | Ultomiris | C5 | anti-ACHR antibody positive | ||
Zilucoplan | D12356 | L04AJ06 | Zilbrysq | C5 | anti-ACHR antibody positive | ||
Ibritumomab tiuxetan | D04489 | V10XX02 | Zevalin | CD20 | CD20 positive | ||
Lutetium (177Lu) dotatate | D11033 | V10XX04 | Lutathera | SSTR2 | somatostatin receptor (SSTR) positive | ||
Lutetium Lu 177 vipivotide tetraxetan | D12335 | V10XX05 | Pluvicto | FOLH1 | PSMA positive | ||
Letrozole and ribociclib | D11068 | Kisqali femara | ESR1, PGR positive HER2 negative |
2099v1 | |||
Tovorafenib | D12291 | (L01EC04) | Ojemda | BRAF RAF1 |
BRAF fusion or BRAF rearrangement or BRAF V600 mutation | 673v1 673v2 |
nt06273 |
Gumarontinib | D12705 | Haiyitan | MET | MET exon 14 skipping | 4233v4 | nt06266 |
Drug | KEGG | ATC | Product | KEGG DISEASE |
Biomarker | KEGG VARIANT |
KEGG NETWORK |
Setmelanotide | D11928 | A08AA12 | Imcivree | H02106 H02060 H02105 |
LEPR, PCSK1, POMC deficiency | ||
Carglumic acid | D07130 | A16AA05 | Carbaglu | H01032 | NAGS deficiency (CPS1 activator) | 162417v1 | nt06010 |
Imiglucerase | D03020 | A16AB02 | Cerezyme | H00126 | GBA deficiency (enzyme replacement) | 2629v1 | nt06014 |
Agalsidase alpha | D02784 | A16AB03 | Replagal | H00125 | GLA deficiency (enzyme replacement) | 2717v1 | nt06014 |
Agalsidase beta | D03228 | A16AB04 | Fabrazyme | H00125 | GLA deficiency (enzyme replacement) | 2717v1 | nt06014 |
Laronidase | D04670 | A16AB05 | Aldurazyme | H00128 | IDUA deficiency (enzyme replacement) | 3425v1 | nt06012 |
Sacrosidase | D05782 | A16AB06 | Sucraid | H00115 | SI deficiency (enzyme replacement) | 6476v1 | |
Alglucosidase alfa | D03207 | A16AB07 | Lumizyme | H01940 | GAA deficiency (enzyme replacement) | 2548v1 | nt06017 |
Galsulfase | D06565 | A16AB08 | Naglazyme | H00131 | ARSB deficiency (enzyme replacement) | 411v1 | nt06012 |
Idursulfase | D04499 | A16AB09 | Elaprase | H00129 | IDS deficiency (enzyme replacement) | 3423v1 | nt06012 |
Velaglucerase alfa | D09029 | A16AB10 | Vpriv | H00126 | GBA deficiency (enzyme replacement) | 2629v1 | nt06014 |
Taliglucerase alfa | D09675 | A16AB11 | Elelyso | H00126 | GBA deficiency (enzyme replacement) | 2629v1 | nt06014 |
Elosulfase | D10333 | A16AB12 | Vimizim | H00123 | GALNS deficiency (enzyme replacement) | 2588v1 | nt06012 |
Asfotase alfa | D10595 | A16AB13 | Strensiq | H00213 | ALPL deficiency (enzyme replacement) | 249v1 | |
Sebelipase alfa | D10377 | A16AB14 | Kanuma | H00148 | LIPA deficiency (enzyme replacement) | 3988v1 | |
Velmanase alfa | D11024 | A16AB15 | Lamzede | H00139 | MAN2B1 deficiency (enzyme replacement) | 4125v1 | |
Idursulfase beta | D11025 | A16AB16 | Hunterase | H00129 | IDS deficiency (enzyme replacement) | 3423v1 | nt06012 |
Cerliponase alfa | D10813 | A16AB17 | Brineura | H00149 | TPP1 deficiency (enzyme replacement) | 1200v1 | |
Vestronidase alfa | D11004 | A16AB18 | MepseVII | H00132 | GUSB deficiency (enzyme replacement) | 2990v1 | nt06012 |
Pegvaliase | D11077 | A16AB19 | Palynziq | H00167 | PAH deficiency (substitution by PAL activity) | 5053v1 | |
Pegunigalsidase alfa | D11685 | A16AB20 | Elfabrio | H00125 | GLA deficiency (enzyme replacement) | 2717v1 | |
Avalglucosidase alfa | D11744 | A16AB22 | Nexviazyme | H01940 | GAA deficiency (enzyme replacement) | 2548v1 | nt06017 |
Cipaglucosidase alfa | D11798 | A16AB23 | Pombiliti | H01940 | GAA deficiency (enzyme replacement) | 2548v1 | nt06017 |
Olipudase alfa | D10820 | A16AB25 | Xenpozyme | H00137 | SMPD1 deficiency (enzyme replacement) | 6609v1 | |
Eladocagene exuparvovec | D12407 | A16AB26 | Upstaza | H01161 | DDC deficiency (gene therapy) | 1644v1 | nt06028 |
Sodium phenylbutyrate | D05868 | A16AX03 | Buphenyl | H01398 | ASS1, CPS1, OTC deficiency | 445v1 1373v1 5009v1 |
|
Nitisinone | D05177 | A16AX04 | Orfadin | H00165 | FAH deficiency (HPD inhibitor) | 2184v1 | nt06016 |
Miglustat | D05032 | A16AX06 | Zavesca | H00126 | GBA deficiency (UGCG inhibitor) | 2629v1 | nt06014 |
Sapropterin | D01798 | A16AX07 | Kuvan | H00167 | QDPR deficiency (cofactor replacement) | 5860v1 | nt06016 |
Glycerol phenylbutyrate | D10127 | A16AX09 | Ravicti | H01398 | ASS1, CPS1, OTC deficiency | 445v1 1373v1 5009v1 |
|
Eliglustat | D09894 | A16AX10 | Cerdelga | H00126 | GBA deficiency (UGCG inhibitor) CYP2D6 polymorphism |
2629v1 | nt06014 |
Migalastat | D05031 | A16AX14 | Galafold | H00125 | GLA variant (migalastat amenable) | 2717v2 | nt06014 |
Triheptanoin | D11465 | A16AX17 | Dojolvi | ACADVL, CPT2, HADHA, HADHB mutation (fatty acid supplement) | |||
Lumasiran | D11926 | A16AX18 | Oxlumo | H00117 | AGXT mutation | ||
Fosdenopterin | D11780 | A16AX19 | Nulibry | H02311 | MOCS1 deficiency (cofactor replacement) | 4337v1 | nt06025 |
Lonafarnib | D04768 | A16AX20 | Zokinvy | H00601 | LMNA mutation ZMPSTE24 mutation |
||
Elapegademase | D11017 | L03AX21 | Revcovi | H02309 | ADA deficiency (enzyme replacement) | 100v1 | |
Efgartigimod alfa | D11876 | L04AA58 | Vyvgart | H01594 | anti-ACHR antibody positive | ||
Eteplirsen | D09900 | M09AX06 | Exondys 51 | H01963 | DMD mutation (exon 51 skipping amenable) | 1756v1 | |
Golodirsen | D11707 | M09AX08 | Vyondys 53 | H01963 | DMD mutation (exon 53 skipping amenable) | 1756v1 | |
Onasemnogene abeparvovec | D11559 | M09AX09 | Zolgensma | H00455 | bi-allelic SMN1 mutations | ||
Viltolarsen | D11528 | M09AX12 | Viltepso | H01963 | DMD mutation (exon 53 skipping amenable) | 1756v1 | |
Casimersen | D11988 | M09AX13 | Amondys 45 | H01963 | DMD mutation (exon 45 skipping amenable) | 1756v1 | |
Ganaxolone | D04300 | N03AX27 | Ztalmy | H01819 | CDKL5 mutation | ||
Tofersen | D11811 | N07XX22 | Qalsody | H00058 | SOD1 mutation | 6647v1 | |
Ivacaftor | D09916 | R07AX02 | Kalydeco | H00218 | CFTR mutation | 1080v1 | |
Lumacaftor and ivacaftor | D10685 | R07AX30 | Orkambi | H00218 | CFTR mutation | 1080v1 | |
Tezacaftor and ivacaftor | D11042 | R07AX31 | Symdeko | H00218 | CFTR mutation | 1080v1 | |
Elexacaftor, ivacaftor and tezacaftor | D11700 | R07AX32 | Trikafta | H00218 | CFTR mutation | 1080v1 | |
Apadamtase alfa and cinaxadamtase alfa | D12835 | (B01AD13) | Adzynma | H00225 | ADAMTS13 mutation (enzyme replacement) |
Drug | KEGG | ATC | Product | Target | Biomarker |
Maraviroc | D06670 | J05AX09 | Selzentry | CCR5 | CCR5-tropic HIV-1 (R5 variant) |
Drug | KEGG | ATC | Biomarker | KEGG VARIANT |
Omeprazole | D00455 D05259 |
A02BC01 | CYP2C19 polymorphism | 1557v1 |
Pantoprazole | D02593 | A02BC02 | CYP2C19 polymorphism | 1557v1 |
Lansoprazole | D00355 | A02BC03 | CYP2C19 polymorphism | 1557v1 |
Rabeprazole | D00724 | A02BC04 | CYP2C19 polymorphism | 1557v1 |
Esomeprazole | D01984 D04056 D10120 |
A02BC05 | CYP2C19 polymorphism | 1557v1 |
Dexlansoprazole | D08903 | A02BC06 | CYP2C19 polymorphism | 1557v1 |
Metoclopramide | D05008 | A03FA01 | CYB5R deficiency G6PD deficiency |
2539v1 |
Palonosetron | D05343 | A04AA05 | CYP2D6 polymorphism | 1565v1 |
Dronabinol | D00306 | A04AD10 | CYP2C9 polymorphism | 1559v1 |
Odevixibat | D11716 | A05AX05 | ABCB11 mutation | 8647v1 |
Dextromethorphan and bupropion | D12493 | N06AX62 N07XX59 |
CYP2D6 polymorphism | 1565v1 |
Sulfasalazine | D00448 | A07EC01 | G6PD deficiency | 2539v1 |
Glibenclamide (Glyburide) | D00336 | A10BB01 | G6PD deficiency | 2539v1 |
Chlorpropamide | D00271 | A10BB02 | G6PD deficiency | 2539v1 |
Glipizide | D00335 | A10BB07 | G6PD deficiency | 2539v1 |
Glimepiride | D00593 | A10BB12 | G6PD deficiency | 2539v1 |
Nateglinide | D01111 | A10BX03 | CYP2C9 polymorphism | 1559v1 |
Warfarin | D00564 | B01AA03 | VKORC1 rs9923231 CYP2C9 polymorphism PROC deficiency PROS deficiency |
79001v1 1559v1 |
Clopidogrel | D00769 | B01AC04 | CYP2C19 polymorphism | 1557v1 |
Ticagrelor | D09017 | B01AC24 | CYP2C19 polymorphism | 1557v1 |
Eltrombopag | D03978 | B02BX05 | Factor V Leiden ATIII deficiency |
2153v1 |
Lusutrombopag | D10476 | B02BX07 | Factor V Leiden Prothrombin 20210A ATIII deficiency PROC deficiency PROS deficiency |
2153v1 2147v1 |
Avatrombopag | D10307 | B02BX08 | Factor V Leiden Prothrombin 20210A ATIII deficiency PROC deficiency PROS deficiency |
2153v1 2147v1 |
Quinidine | D00642 D02272 |
C01BA01 | CYP2D6 polymorphism | 1565v1 |
Procainamide | D08421 D00477 |
C01BA02 | NAT polymorphism | 9v1 10v1 |
Propafenone | D00640 | C01BC03 | CYP2D6 polymorphism | 1565v1 |
Isosorbide dinitrate | D00516 | C01DA08 | CYB5R deficiency | |
Isosorbide mononitrate | D00630 | C01DA14 | CYB5R deficiency | |
Mavacamten | D12265 | C01EB24 | CYP2C19 polymorphism | 1557v1 |
Hydralazine and isosorbide | D10209 | NAT polymorphism | 9v1 10v1 |
|
Propranolol | D00483 | C07AA05 | CYP2D6 polymorphism | 1565v1 |
Metoprolol | D00601 D00635 |
C07AB02 | CYP2D6 polymorphism | 1565v1 |
Carvedilol | D00255 D03415 |
C07AG02 | CYP2D6 polymorphism | 1565v1 |
Rosuvastatin | D01915 | C10AA07 | SLCO1B1 polymorphism | |
Doxepin | D00814 | D04AX01 N06AA12 |
CYP2C19 polymorphism CYP2D6 polymorphism |
1557v1 1565v1 |
Amikacin | D00865 | D06AX12 | MT-RNR1 (m.1555A>G) | 4549v1 |
Mafenide | D01166 | D06BA03 | G6PD deficiency | 2539v1 |
Dapsone | D00592 | D10AX05 J04BA02 |
G6PD deficiency | 2539v1 |
Abrocitinib | D11400 | D11AH08 | CYP2C19 polymorphism | 1557v1 |
Flibanserin | D02577 | G02CX02 | CYP2C9 polymorphism CYP2C19 polymorphism CYP2D6 polymorphism |
1559v1 1557v1 1565v1 |
Drospirenone and ethinylestradiol | D09741 | G03AA12 | CYP2C19 polymorphism | 1557v1 |
Tolterodine | D01148 | G04BD07 | CYP2D6 polymorphism | 1565v1 |
Darifenacin | D01699 | G04BD10 | CYP2D6 polymorphism | 1565v1 |
Fesoterodine | D08923 | G04BD11 | CYP2D6 polymorphism | 1565v1 |
Elagolix | D09336 | H01CC03 | SLCO1B1 polymorphism | |
Parathyroid hormone | D05364 | H05AA03 | CASR positive | |
Sulfamethoxazole and trimethoprim | D00285 | J01EE01 | G6PD deficiency | 2539v1 |
Tobramycin | D00063 | J01GB01 | MT-RNR1 (m.1555A>G) | 4549v1 |
Plazomicin | D10655 | J01GB14 | MT-RNR1 (m.1555A>G) | 4549v1 |
Nalidixic acid | D00183 | J01MB02 | G6PD deficiency | 2539v1 |
Nitrofurantoin | D00439 | J01XE01 | G6PD deficiency | 2539v1 |
Voriconazole | D00578 | J02AC03 | CYP2C19 polymorphism | 1557v1 |
Rifampin, isoniazid, and pyrazinamide | D10210 | J04AM05 | NAT polymorphism | 9v1 10v1 |
Abacavir | D00891 | J05AF06 | HLA-B*5701 | |
Efavirenz | D00896 | J05AG03 | CYP2B6 | 1555v1 |
Dolutegravir | D10113 | J05AJ03 | UGT1A1 polymorphism | 54658v1 |
Sofosbuvir | D10366 | J05AP08 | IL28B rs12979860 | 282617v1 |
Dasabuvir, ombitasvir, paritaprevir and ritonavir |
D10582 | J05AP52 | IL28B rs12979860 | 282617v1 |
Elbasvir and grazoprevir | D10778 | J05AP54 | IL28B allele carrier | |
Mercaptopurine | D00161 | L01BB02 | TPMT polymorphism | 7172v1 |
Thioguanine | D06109 | L01BB03 | TPMT polymorphism | 7172v1 |
Fluorouracil | D00584 | L01BC02 | DPYD deficiency | |
Capecitabine | D01223 | L01BC06 | DPYD deficiency | |
Irinotecan | D01061 | L01CE02 | UGT1A1 polymorphism | 54658v1 |
Lapatinib | D04024 | L01EH01 | HLA-DQA1*0201 HLA-DRB1*0701 |
|
Nilotinib | D06413 | L01EA03 | UGT1A1 polymorphism | 54658v1 |
Pazopanib | D05380 | L01EX03 | UGT1A1 polymorphism | 54658v1 |
Sacituzumab govitecan | D10985 | L01FX17 | UGT1A1 polymorphism | 54658v1 |
Cisplatin | D00275 | L01XA01 | TPMT polymorphism | 7172v1 |
Belinostat | D08870 | L01XH04 | UGT1A1 polymorphism | 54658v1 |
Belzutifan | D11954 | L01XX74 | CYP2C19 polymorphism UGT2B17 polymorphism |
1557v1 |
Peginterferon alfa-2b | D02748 | L03AB10 | IL28B rs12979860 | |
Mycophenolic acid | D00752 D05095 D05096 |
L04AA06 | HPRT deficiency | |
Etrasimod | D10931 | L04AE05 | CYP2C9 polymorphism | 1559v1 |
Azathioprine | D00238 | L04AX01 | TPMT polymorphism | 7172v1 |
Lenalidomide | D04687 | L04AX04 | Chromosome 5q deletion | |
Piroxicam | D00127 | M01AC01 | CYP2C9 polymorphism | 1559v1 |
Celecoxib | D00567 | L01XX33 M01AH01 |
CYP2C9 polymorphism | 1559v1 |
Flurbiprofen | D00330 D02290 |
M01AE09 M02AA19 R02AX01 S01BC04 |
CYP2C9 polymorphism | 1559v1 |
Succinylcholine | D00766 | M03AB01 | BCHE deficiency | |
Carisoprodol | D00768 | M03BA02 | CYP2C19 polymorphism | 1557v1 |
Allopurinol | D07564 | M04AA01 | HLA-B*5801 | |
Lesinurad | D09921 | M04AB05 | CYP2C9 polymorphism | 1559v1 |
Pegloticase | D09316 | M04AX02 | G6PD deficiency | |
Sevoflurane | D00547 | N01AB08 | RYR1 positive | |
Sodium oxybate | D05866 | N01AX11 N07XX04 |
ALDH5A1 deficiency (Succinic semialdehyde dehydrogenase deficiency) |
|
Prilocaine and lidocaine | D02740 | N01BB52 N01BB54 |
CYB5R deficiency G6PD deficiency |
2539v1 |
Tramadol and acetaminophen | D09999 | N02AJ13 | CYP2D6 polymorphism | 1565v1 |
Tramadol | D01355 | N02AX02 | CYP2D6 polymorphism | 1565v1 |
Oliceridine | D11214 | N02AX07 | CYP2D6 polymorphism | 1565v1 |
Phenytoin | D00512 D02103 |
N03AB02 | HLA-B*1502 | |
Fosphenytoin | D02096 | N03AB05 | HLA-B*1502 CYP2C9 polymorphism |
1559v1 |
Carbamazepine | D00252 | N03AF01 | HLA-B*1502 HLA-A*3101 |
|
Oxcarbazepine | D00533 | N03AF02 | HLA-B*1502 | |
Valproic acid | D00399 D00304 D00710 |
N03AG01 | POLG deficiency CPS1,OTC,NAGS / ASS1,ASL / ARG deficiency (Urea cycle disorders) |
1373v1 5009v1 162417v1 445v1 435v1 383v1 |
Lacosamide | D07299 | N03AX18 | CYP2C19 polymorphism | 1557v1 |
Brivaracetam | D08879 | N03AX23 | CYP2C19 polymorphism | 1557v1 |
Perphenazine | D00503 | N05AB03 | CYP2D6 polymorphism | 1565v1 |
Thioridazine | D00798 | N05AC02 | CYP2D6 polymorphism | 1565v1 |
Pimozide | D00560 | N05AG02 | CYP2D6 polymorphism | 1565v1 |
Clozapine | D00283 | N05AH02 | CYP2D6 polymorphism | 1565v1 |
Risperidone | D00426 | N05AX08 | CYP2D6 polymorphism | 1565v1 |
Aripiprazole | D01164 D10364 |
N05AX12 | CYP2D6 polymorphism | 1565v1 |
Iloperidone | D02666 | N05AX14 | CYP2D6 polymorphism | 1565v1 |
Brexpiprazole | D10309 | N05AX16 | CYP2D6 polymorphism | 1565v1 |
Diazepam | D00293 | N05BA01 | CYP2C19 polymorphism | 1557v1 |
Clobazam | D01253 | N05BA09 | CYP2C19 polymorphism | 1557v1 |
Desipramine | D00812 | N06AA01 | CYP2D6 polymorphism | 1565v1 |
Imipramine | D00815 | N06AA02 | CYP2D6 polymorphism | 1565v1 |
Clomipramine | D00811 | N06AA04 | CYP2D6 polymorphism | 1565v1 |
Amitriptyline | D00809 | N06AA09 | CYP2D6 polymorphism | 1565v1 |
Trimipramine | D02408 | N06AA06 | CYP2D6 polymorphism | 1565v1 |
Nortriptyline | D00816 | N06AA10 | CYP2D6 polymorphism | 1565v1 |
Protriptyline | D00484 | N06AA11 | CYP2D6 polymorphism | 1565v1 |
Fluoxetine | D00823 | N06AB03 | CYP2D6 polymorphism | 1565v1 |
Citalopram | D00822 | N06AB04 | CYP2C19 polymorphism CYP2D6 polymorphism |
1557v1 1565v1 |
Paroxetine | D02260 D05374 D05375 |
N06AB05 | CYP2D6 polymorphism | 1565v1 |
Fluvoxamine | D00824 | N06AB08 | CYP2D6 polymorphism | 1565v1 |
Escitalopram | D02567 | N06AB10 | CYP2C19 polymorphism CYP2D6 polymorphism |
1557v1 1565v1 |
Nefazodone | D00819 | N06AX06 | CYP2D6 polymorphism | 1565v1 |
Venlafaxine | D00821 | N06AX16 | CYP2D6 polymorphism | 1565v1 |
Duloxetine | D01179 | N06AX21 | CYP2D6 polymorphism | 1565v1 |
Vortioxetine | D10185 | N06AX26 | CYP2D6 polymorphism | 1565v1 |
Modafinil | D01832 | N06BA07 | CYP2D6 polymorphism | 1565v1 |
Atomoxetine | D02574 | N06BA09 | CYP2D6 polymorphism | 1565v1 |
Chlordiazepoxide and amitriptyline | D10207 | N06CA01 | CYP2D6 polymorphism | 1565v1 |
Galantamine | D02173 | N06DA04 | CYP2D6 polymorphism | 1565v1 |
Lecanemab | D11678 | N06DX04 | APOE epsilon4 homozygotes | |
Cevimeline | D00661 | N07AX03 | CYP2D6 polymorphism | 1565v1 |
Lofexidine | D04765 | N07BC04 | CYP2D6 polymorphism | 1565v1 |
Tetrabenazine | D08575 | N07XX06 | CYP2D6 polymorphism | 1565v1 |
Valbenazine | D10999 | N07XX13 | CYP2D6 polymorphism | 1565v1 |
Deutetrabenazine | D10701 | N07XX16 | CYP2D6 polymorphism | 1565v1 |
Dextromethorphan and quinidine | D10208 | N07XX59 | CYP2D6 polymorphism | 1565v1 |
Chloroquine | D02125 | P01BA01 | G6PD deficiency | 2539v1 |
Primaquine | D02126 | P01BA03 | G6PD deficiency | 2539v1 |
Tafenoquine | D10670 | P01BA07 | G6PD deficiency | 2539v1 |
Quinine sulfate | D02262 | P01BC01 | G6PD deficiency CYP2D6 polymorphism |
2539v1 1565v1 |
Indacaterol | D09319 | R03AC18 | UGT1A1 polymorphism | 54658v1 |
Arformoterol | D02981 | UGT1A1 polymorphism CYP2D6 polymorphism |
54658v1 1565v1 |
|
Codeine | D03580 | R05DA04 | CYP2D6 polymorphism | 1565v1 |
Sodium nitrite | D05865 | V03AB08 | G6PD deficiency | 2539v1 |
Methylene blue | D02312 | V03AB17 | G6PD deficiency | 2539v1 |
Rasburicase | D05704 | V03AF07 | G6PD deficiency CYB5R deficiency |
2539v1 |
Succimer | D00572 | G6PD deficiency | 2539v1 |